Patents Assigned to Theratechnologies Inc.
-
Publication number: 20090088383Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: September 26, 2008Publication date: April 2, 2009Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdlaine
-
Publication number: 20090011997Abstract: A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and/or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).Type: ApplicationFiled: July 7, 2008Publication date: January 8, 2009Applicant: Theratechnologies Inc.Inventors: Krishna G. Peri, Abdelkrim Habi
-
Publication number: 20090011985Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: October 23, 2007Publication date: January 8, 2009Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Publication number: 20080249017Abstract: Stabilized solid and liquid pharmaceutical formulations comprising a GHRH molecules as active ingredient, and more particularly GHRH analogs including [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises an anionic surfactant and a non-reducing sugar, and has a pH of about 4.0 to about 7.5. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it.Type: ApplicationFiled: April 4, 2008Publication date: October 9, 2008Applicant: THERATECHNOLOGIES INC.Inventors: Helen Loughrey, Byeong Chang
-
Patent number: 7414029Abstract: Antagonistic peptides of prostaglandin E2 receptor subtype EP4 and their use in the treatment or prevention of medical conditions associated with oligouric nephropathy, bone resorption, abnormal intestinal crypt cell proliferation or patency of the ductus arteriosus and the like are provided herein. The antagonistic peptides of the present invention can include the following formula: X-A-RnYm wherein “X” is a hydrogen atom or an amine protecting group producing a carbamate or an amide when reacting with the amine; “A” is L-(4,4?)-biphenylalanine or D-(4,4?)-biphenylalanine; “R” is an amino acid selected from the group consisting of threonine, serine, tyrosine, glutamic acid, alanine, leucine and glycine; “Y” is lysine; “n” is an integer ranging from 5 to 7; and “m” is an integer ranging from 0 to 2.Type: GrantFiled: October 19, 2004Date of Patent: August 19, 2008Assignee: Theratechnologies, Inc.Inventors: Krishna G. Peri, Serge Moffett, Daniel Abran, Annie Bergeron
-
Publication number: 20080167222Abstract: The present invention provides methods for using growth hormone releasing factor analogs of the formula (A), X-GRF Peptide, and pharmaceutically acceptable salts thereof, for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.Type: ApplicationFiled: October 20, 2004Publication date: July 10, 2008Applicant: THERATECHNOLOGIES INC.Inventors: Bruno Lussier, Luc Vachon, Soraya Allas, Thierry Abribat
-
Patent number: 7316997Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: October 20, 2004Date of Patent: January 8, 2008Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Publication number: 20060292613Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.Type: ApplicationFiled: July 12, 2006Publication date: December 28, 2006Applicant: Theratechnologies Inc.Inventors: Krishna Peri, Serge Moffett, Daniel Abran
-
Patent number: 7094761Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.Type: GrantFiled: October 28, 2004Date of Patent: August 22, 2006Assignee: Theratechnologies Inc.Inventors: Krishna G. Peri, Serge Moffett, Daniel Abran
-
Patent number: 7067488Abstract: The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof: X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-val-Lys-Gly-Arg-Y (SEQ ID NO. 1) wherein X is a rigidifying hydrophobic moiety and wherein Y is selected from the group consisting of OH, NH2 and Gly-OH. Moreover, the present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of a peptide of the present invention, or a pharmaceutically acceptable salt thereof, in association with at least one constituent selected from a pharmaceutically acceptable carrier, diluent, and excipient.Type: GrantFiled: September 25, 2003Date of Patent: June 27, 2006Assignee: TheraTechnologies Inc.Inventors: Denis Gravel, Krishna Peri, Thierry Abribat, Abdelkrim Habi
-
Publication number: 20050197288Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: October 20, 2004Publication date: September 8, 2005Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Publication number: 20050164949Abstract: Antagonistic peptides of prostaglandin E2 receptor subtype EP4 and their use in the treatment or prevention of medical conditions associated with oligouric nephropathy, bone resorption, abnormal intestinal crypt cell proliferation or patency of the ductus arteriosus and the like are provided herein. The antagonistic peptides of the present invention can include the following formula: X-A?R?nYm wherein “X” is a hydrogen atom or an amine protecting group producing a carbamate or an amide when reacting with the amine; “A” is L-(4,4?)-biphenylalanine or D-(4,4?)-biphenylalanine; “R” is an amino acid selected from the group consisting of threonine, serine, tyrosine, glutamic acid, alanine, leucine and glycine; “Y” is lysine; “n” is an integer ranging from 5 to 7; and “m” is an integer ranging from 0 to 2.Type: ApplicationFiled: October 19, 2004Publication date: July 28, 2005Applicant: THERATECHNOLOGIES INC.Inventors: Krishna Peri, Serge Moffett, Daniel Abran, Annie Bergeron
-
Publication number: 20050059604Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.Type: ApplicationFiled: October 28, 2004Publication date: March 17, 2005Applicant: Theratechnologies Inc.Inventors: Krishna Peri, Serge Moffett, Daniel Abran
-
Patent number: 6864239Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.Type: GrantFiled: March 27, 2003Date of Patent: March 8, 2005Assignee: Theratechnologies Inc.Inventors: Krishna G. Peri, Serge Moffett, Daniel Abran
-
Publication number: 20040171534Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.Type: ApplicationFiled: August 7, 2002Publication date: September 2, 2004Applicant: Theratechnologies, Inc.Inventors: Denis Gravel, Abdelkrim Habi, Paul Brazeau
-
Patent number: 6458764Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.Type: GrantFiled: September 3, 1999Date of Patent: October 1, 2002Assignee: Theratechnologies Inc.Inventors: Denis Gravel, Abdelkrim Habi, Paul Brazeau
-
Patent number: 6194384Abstract: The present invention relates to a long-acting galenical formulation of GRF peptides, GRF and/or analogs thereof which comprises about 1 to about 100 mg of a GRF peptide, fragment or analog thereof pressed from about 1 to about 100 kg/mm2 in a tablet for parenteral administration, whereby these GRF peptides are released as the tablet is eroded.Type: GrantFiled: August 18, 1998Date of Patent: February 27, 2001Assignee: Theratechnologies, Inc.Inventors: Paul Brazeau, Denis Gravel
-
Patent number: 6106544Abstract: The present invention relates to a device for closing cutaneous wounds without sutures, which comprises a pair of three-dimensionally flexible strips adopted to be positioned on each side of a wound and formed of a plurality of laterally spaced apart elongated anchoring members extending side-by-side in succession and transversely of the wound and being interconnected in a three-dimensionally flexible manner to follow the lips of an open wound.Type: GrantFiled: November 30, 1998Date of Patent: August 22, 2000Assignee: Theratechnologies, Inc.Inventor: Paul Brazeau
-
Patent number: 6020311Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.Type: GrantFiled: September 8, 1998Date of Patent: February 1, 2000Assignee: Theratechnologies, Inc.Inventors: Paul Brazeau, Denis Gravel
-
Patent number: 5939386Abstract: The present invention relates to chimeric fatty body-pro-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-pro-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring one or several hydrophobic tails to the GRF, or by substituting one or several amino-acids by a pseudomicellar residue in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.Type: GrantFiled: August 23, 1996Date of Patent: August 17, 1999Assignee: Theratechnologies Inc.Inventors: Michel Ibea, Thierry Abribat, Paul Brazeau